Lilly's Moat Still Intact After Halting Heart Drug Study
October 12, 2015 at 12:18 PM EDT
Given the stock's major pullback on the discontinuation announcement, we now see Lilly as fairly valued.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.